DNA repair defects in prostate cancer and the underlying mechanism of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition—alone and in combination with other agents—play an important role in the management of prostate cancer. Furthermore, PARP inhibitors have shown evidence of efficacy for mCRPC and have been recently approved or are under review by the FDA.
Learn about recent approvals of PARP inhibitors and more in an expert overview inReview program or at your chapter in a small interactive meeting. The expert will also provide insight into the rationale for and mechanisms of targeting DNA repair deficiencies in prostate cancer, practical considerations associated with genetic testing, evidence on the efficacy and safety of PARP inhibitors, and considerations for appropriate and effective integration of PARP inhibitor therapy for prostate cancer management.
This activity has been designed to meet the educational needs of urologists, oncologists, and other clinicians involved in the management of prostate cancer.
Emmanuel Antonarakis, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland
Learn from one of our clinical experts by requesting a live meeting at your chapter! In the context of a small, interactive group discussion, an expert in the field will review the rationale for and mechanisms of targeting DNA repair deficiencies in prostate cancer, practical considerations associated with genetic testing, evidence on the efficacy and safety of PARP inhibitors, and considerations for appropriate and effective integration of PARP inhibitor therapy for prostate cancer management.
Download and complete the Meeting Request Form (or complete our online form) to request a live in-person meeting or turn-key virtual meeting with our expert faculty.
By requesting a meeting, you are attesting that you have read the CME Information for this activity.
Emmanuel Antonarakis, MD
This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, Inc., and Merck & Co., Inc.
Your meeting request has been submitted.
We invite you to learn more about PeerView's Regional Meetings here.
